Sukh Makhnoon

Dr. Sukh Makhnoon


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2019 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
SMSukh Makhnoon
Sukh Makhnoon
BSBrian H. Shirts
Brian H. Shirts
DBDeborah J. Bowen
Deborah J. Bowen

24 November 2022 in Cancer Medicine
Verified
Journal Article
Open access
SMSukh Makhnoon
Sukh Makhnoon
BLBrooke Levin
Brooke Levin
MEMegan Ensinger
Megan Ensinger
KMKristin Mattie
Kristin Mattie
RVRobert J. Volk
Robert J. Volk
SPSusan K. Peterson
Susan K. Peterson
Background: Clinical interpretation of genetic test results is complicated by variants of uncertain significance (VUS) that have an unknown impact on health but can be clarified through reclassification. There is little empirical evidence regarding VUS reclassification in oncology care settings, including the prevalence and outcomes of reclassification, and racial/ethnic differences.Methods: This was a retrospective analysis of persons with and without a personal history of cancer carrying VUS (with or without an accompanying pathogenic or likely pathogenic [P/LP] variant) in breast, ovarian, and colorectal cancer predisposition genes seen at four cancer care settings (in Texas, Florida, Ohio, and New Jersey) between 2013 and 2019.Results: In 2715 individuals included in the study, 3261 VUS and 313 P/LP variants were reported; 8.1% of all individuals with VUS experienced reclassifications and rates varied significantly among cancer care settings from 4.81% to 20.19% (overall p < 0.001). Compared to their prevalence in the overall sample, reclassification rates for Black individuals were higher (13.6% vs. 19.0%), whereas the rates for Asian individuals were lower (6.3% vs. 3.5%) and rates for White and Hispanic individuals were proportional. Two‐year prevalence of VUS reclassification remained steady between 2014 and 2019. Overall, 11.3% of all reclassified VUS resulted in clinically actionable findings and 4.6% subsequently changed individuals' clinical managements.Conclusions: The findings from this large multisite study suggest that VUS reclassification alters clinical management, has implications for precision cancer prevention, and highlights the need for implementing practices and solutions for efficiently returning reinterpreted genetic test results.

19 July 2018 in Journal of Community Genetics
Verified
Journal Article
Closed access
PDF file
SMSukh Makhnoon
Sukh Makhnoon
LGLauren Thomas Garrett
Lauren Thomas Garrett
WBWylie Burke
Wylie Burke
Deborah J. BowenDeborah J. Bowen
Deborah J. Bowen
BSBrian H. Shirts
Brian H. Shirts

12 April 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
SMSukh Makhnoon
Sukh Makhnoon
EBErica M. Bednar
Erica M. Bednar
KKKate J. Krause
Kate J. Krause
SPSusan K. Peterson
Susan K. Peterson
MLMaria A. Lopez‐Olivo
Maria A. Lopez‐Olivo

23 August 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
BABanu K. Arun
Banu K. Arun
SPSusan K. Peterson
Susan K. Peterson
LSLilian E. Sweeney
Lilian E. Sweeney
RBRachel D. Bluebond
Rachel D. Bluebond
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
AKAnne C. Kushwaha
Anne C. Kushwaha

11 July 2024 in Genetics in Medicine Open
Verified
Journal Article
Open access
ATAbhinav Thummala
Abhinav Thummala
RSRhea Sudhakaran
Rhea Sudhakaran
AGAnoop Gurram
Anoop Gurram
JMJacqueline Mersch
Jacqueline Mersch
ABAlexa Badalamenti
Alexa Badalamenti
SMSukh Makhnoon
Sukh Makhnoon
A primary challenge in clinical genetics is accurate interpretation of identified variants and relaying the information to patients and providers. Inconsistencies around handling variant reclassifications and notifying patients, combined with the lack of prescriptive guidelines on re-evaluation, reanalysis, and return of variants, has created practice challenges. Although relevant empirical work has emerged, the scope and outcomes of this research have not been characterized. We conducted a systematic literature review of variant reclassification and recontact research (2013-2023) across subdisciplines of medical genetics. Of the 159 nonduplicate records screened, we summarize findings from 54 included research articles describing variant reclassification frequencies, outcomes, and stakeholder perspectives on recontact. The included articles reported on active reclassification (n = 20), passive reclassification (n = 13), stakeholder surveys (n = 11), qualitative interviews (n = 7), and reanalysis of published or ClinVar data (n = 3). On average, active and passive approaches yielded different reclassification frequencies-31% and 20%, respectively, which were considerably higher than ClinVar (<0.1%-6.4%). Despite a wealth of data on individual stakeholder perspectives and opinions on reclassification, recontact, and consensus on the need for standardization in this space, opinions differ on how to develop and implement standardized processes. Many active reclassification studies reapplied standard variant classification guideline to previously reported variants-thus demonstrating the number of variants that would be successfully reclassified if reinterpretation and reanalysis were performed routinely. Research gaps identified include the need for understanding practices and opinions of nongenetics providers and engaging in deliberative democracy exercises to reach consensus on these issues.